170 related articles for article (PubMed ID: 32987824)
1. Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes.
Fotheringham AK; Bagger JI; Borg DJ; McCarthy DA; Holst JJ; Vilsbøll T; Knop FK; Forbes JM
Nutrients; 2020 Sep; 12(10):. PubMed ID: 32987824
[TBL] [Abstract][Full Text] [Related]
2. Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals.
Bagger JI; Knop FK; Lund A; Holst JJ; Vilsbøll T
Diabetologia; 2014 Aug; 57(8):1720-5. PubMed ID: 24879388
[TBL] [Abstract][Full Text] [Related]
3. On the role of the gut in diabetic hyperglucagonaemia.
Lund A
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
[TBL] [Abstract][Full Text] [Related]
4. Circulating Ligands of the Receptor for Advanced Glycation End Products and the Soluble Form of the Receptor Modulate Cardiovascular Cell Apoptosis in Diabetes.
Tsoporis JN; Hatziagelaki E; Gupta S; Izhar S; Salpeas V; Tsiavou A; Rigopoulos AG; Triantafyllis AS; Marshall JC; Parker TG; Rizos IK
Molecules; 2020 Nov; 25(22):. PubMed ID: 33182705
[TBL] [Abstract][Full Text] [Related]
5. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
[TBL] [Abstract][Full Text] [Related]
6. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Madsbad S; Holst JJ; Krarup T
Diabetologia; 2007 Apr; 50(4):797-805. PubMed ID: 17225124
[TBL] [Abstract][Full Text] [Related]
7. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
[TBL] [Abstract][Full Text] [Related]
8. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
9. Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect.
Foghsgaard S; Vedtofte L; Andreasen C; Andersen ES; Bahne E; Bagger JI; Svare JA; Holst JJ; Clausen TD; Mathiesen ER; Damm P; Knop FK; Vilsbøll T
Diabetologia; 2017 Jul; 60(7):1344-1353. PubMed ID: 28364253
[TBL] [Abstract][Full Text] [Related]
10. Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes.
Miranda ER; Somal VS; Mey JT; Blackburn BK; Wang E; Farabi S; Karstoft K; Fealy CE; Kashyap S; Kirwan JP; Quinn L; Solomon TPJ; Haus JM
Am J Physiol Endocrinol Metab; 2017 Dec; 313(6):E631-E640. PubMed ID: 28811295
[TBL] [Abstract][Full Text] [Related]
11. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.
Hare KJ; Vilsbøll T; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2010 Apr; 298(4):E832-7. PubMed ID: 20103744
[TBL] [Abstract][Full Text] [Related]
12. Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion.
Lund A; Bagger JI; Christensen M; Grøndahl M; van Hall G; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2016 Nov; 101(11):4377-4384. PubMed ID: 27533305
[TBL] [Abstract][Full Text] [Related]
13. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
15. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
[TBL] [Abstract][Full Text] [Related]
16. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
[TBL] [Abstract][Full Text] [Related]
18. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
19. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2010 Jul; 95(7):3309-17. PubMed ID: 20410219
[TBL] [Abstract][Full Text] [Related]
20. The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; Forman JL; Holst JJ; Knop FK; Vilsbøll T
Eur J Endocrinol; 2022 Oct; 187(4):507-518. PubMed ID: 35977072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
